Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
- PMID: 17151364
- DOI: 10.1056/NEJMoa062867
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Abstract
Background: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.
Methods: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.
Results: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events.
Conclusions: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
Copyright 2006 Massachusetts Medical Society.
Comment in
-
Imatinib in chronic myeloid leukemia.N Engl J Med. 2007 Apr 26;356(17):1780; author reply 1780. doi: 10.1056/NEJMc063767. N Engl J Med. 2007. PMID: 17460235 No abstract available.
Similar articles
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.N Engl J Med. 2003 Oct 9;349(15):1423-32. doi: 10.1056/NEJMoa030513. N Engl J Med. 2003. PMID: 14534335 Clinical Trial.
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457. N Engl J Med. 2003. PMID: 12637609 Clinical Trial.
-
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011. J Clin Oncol. 2006. PMID: 16421422
-
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].Rinsho Byori. 2004 Feb;52(2):136-44. Rinsho Byori. 2004. PMID: 15027317 Review. Japanese.
-
[Tyrosine kinase inhibitors for the treatment of CML].Ther Umsch. 2006 Apr;63(4):249-54. doi: 10.1024/0040-5930.63.4.249. Ther Umsch. 2006. PMID: 16689455 Review. German.
Cited by
-
Design, synthesis, and structure-activity relationship studies of 6H-benzo[b]indeno[1,2-d]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors.RSC Med Chem. 2024 Oct 17. doi: 10.1039/d4md00537f. Online ahead of print. RSC Med Chem. 2024. PMID: 39430953 Free PMC article.
-
Next-Generation Therapies for Multiple Myeloma.Annu Rev Cancer Biol. 2024 Jun;8:351-371. doi: 10.1146/annurev-cancerbio-061421-014236. Epub 2024 Jan 11. Annu Rev Cancer Biol. 2024. PMID: 39364307 Free PMC article.
-
Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel). 2024 Sep 10;14(9):1142. doi: 10.3390/life14091142. Life (Basel). 2024. PMID: 39337925 Free PMC article. Review.
-
Cancer and Heart Failure: Dangerous Liaisons.J Cardiovasc Dev Dis. 2024 Aug 27;11(9):263. doi: 10.3390/jcdd11090263. J Cardiovasc Dev Dis. 2024. PMID: 39330321 Free PMC article. Review.
-
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.MedComm (2020). 2024 Aug 24;5(9):e694. doi: 10.1002/mco2.694. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39184861 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous